Publications

Diabetes mellitus and chronic kidney disease are closely interconnected global health challenges with profound clinical, economic, and societal implications. Diabetes is one of the leading causes of chronic kidney disease worldwide, and diabetic kidney disease represents the most common cause of end-stage kidney disease. The rising global prevalence of both type 1 and type 2 diabetes has contributed to a substantial increase in kidney-related morbidity and mortality, particularly in low- and middle-income countries. The coexistence of diabetes and kidney disease accelerates disease progression, complicates management, and significantly worsens patient outcomes. This comprehensive review examines the epidemiology, shared pathophysiological mechanisms, clinical manifestations, diagnostic approaches, and therapeutic implications of diabetes-related kidney disease. Key mechanistic pathways including chronic hyperglycemia, glomerular hyperfiltration, oxidative stress, advanced glycation end-product formation, renin–angiotensin–aldosterone system activation, inflammation, and fibrosis are discussed in detail. The review also explores diagnostic challenges, emerging biomarkers, and the differentiation of diabetic kidney disease from other nephropathies. Current strategies for prevention and management, including glycemic control, blood pressure and lipid management, renin–angiotensin–aldosterone system inhibition, lifestyle modification, and newer pharmacologic therapies such as sodium-glucose cotransporter-2 inhibitors and glucagonlike peptide-1 receptor agonists, are critically evaluated. Special populations, including pediatric, elderly, and socioeconomically disadvantaged groups, are highlighted to emphasize disparities in disease burden and access to care. The review underscores the importance of early detection, patient education, self-management, and integrated care models. Addressing the growing burden of diabetes-associated kidney disease requires a multidisciplinary approach, equity-focused health policies, and continued research into targeted therapies and early diagnostic tools.